BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 20588175)

  • 1. NKX3.1 as a marker of prostatic origin in metastatic tumors.
    Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
    Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
    Jia L; Jiang Y; Michael CW
    Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
    Lane Z; Hansel DE; Epstein JI
    Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry in diagnostic surgical pathology of the prostate.
    Hameed O; Humphrey PA
    Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes.
    Roh MS; Hong SH
    J Korean Med Sci; 2002 Aug; 17(4):512-7. PubMed ID: 12172048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of NKX3.1 immunohistochemistry in the differential diagnosis of seminal vesicles versus prostatic tissue in needle biopsy.
    Pitra T; Pivovarcikova K; Alaghehbandan R; Compérat EM; Hora M; Rogala J; Slisarenko M; Michal M; Hes O
    Ann Diagn Pathol; 2020 Dec; 49():151644. PubMed ID: 33126153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of NKX 3.1 and HOXB 13 in bone metastases originating from prostatic carcinoma among the Egyptian males.
    Abouhashem NS; Salah S
    Pathol Res Pract; 2020 Oct; 216(10):153221. PubMed ID: 32979741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
    Osunkoya AO; Epstein JI
    Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma.
    Kraus TS; Cohen C; Siddiqui MT
    Diagn Pathol; 2010 Sep; 5():63. PubMed ID: 20863373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
    Parwani AV; Marlow C; Demarzo AM; Mikolajczyk SD; Rittenhouse HG; Veltri RW; Chan TY
    Am J Surg Pathol; 2006 Oct; 30(10):1231-6. PubMed ID: 17001152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
    Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of NKX3.1, Prostatic Specific Antigen and Prostatic Specific Alkaline Phosphatase in Cytology Specimens of Metastatic Prostatic Carcinoma.
    Wang M; Abi-Raad R; Adeniran AJ; Cai G
    J Clin Transl Pathol; 2021 Dec; 1(1):16-20. PubMed ID: 35265947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma.
    Torenbeek R; Lagendijk JH; Van Diest PJ; Bril H; van de Molengraft FJ; Meijer CJ
    Histopathology; 1998 Jan; 32(1):20-7. PubMed ID: 9522212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.
    Varinot J; Cussenot O; Roupret M; Conort P; Bitker MO; Chartier-Kastler E; Cheng L; Compérat E
    Virchows Arch; 2013 Dec; 463(6):803-9. PubMed ID: 24146108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
    Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
    Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKX3.1 Expression in Non-Prostatic Tumors and Characterizing its Expression in Esophageal/Gastroesophageal Adenocarcinoma.
    Mehreen A; Manjee KG; Paralkar D; Paner GP; Lan T
    Adv Anat Pathol; 2024 May; 31(3):202-205. PubMed ID: 38525603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.